Tunlametinib in advanced melanoma with an NRAS gene change after immunotherapy
Tests tunlametinib in adults with NRAS-mutant advanced melanoma after earlier immunotherapy failed.
Plain-language title generated from the registry record
Registry title: RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 4
Where in China
- Fudan University Shanghai Cancer CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fudan University
- Trial code
- NCT07445022
- Record updated
- 3 March 2026
- Original description
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.Read full original descriptionShow less
A Prospective, Open-Label, Multicenter, Real-World Study to Evaluate the Efficacy and Safety of Tunlametinib in Patients With NRAS-Mutant Advanced Melanoma
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Inclusion: Aged ≥18 years (inclusive), male or female; Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma; Prior genetic testing results showing positive NRAS mutation; Patients who have failed prior anti-PD-1/PD-L1 therapy; Able to take oral medications; Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.
Exclusion: Currently participating in other clinical trials of drugs; Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion; Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data; Patients who are pregnant or breastfeeding.